These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
550 related articles for article (PubMed ID: 14717471)
1. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471 [TBL] [Abstract][Full Text] [Related]
2. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672 [TBL] [Abstract][Full Text] [Related]
4. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES). Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030 [TBL] [Abstract][Full Text] [Related]
7. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study. Keiser P; Nassar N; White C; Koen G; Moreno S HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503 [TBL] [Abstract][Full Text] [Related]
8. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM; Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269 [TBL] [Abstract][Full Text] [Related]
9. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials. Torre D; Tambini R; Speranza F HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519 [TBL] [Abstract][Full Text] [Related]
10. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team. Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512 [TBL] [Abstract][Full Text] [Related]
11. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. Abgrall S; Yeni PG; Bouchaud O; Costagliola D; AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754 [TBL] [Abstract][Full Text] [Related]
13. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. Núñez M; Soriano V; Martín-Carbonero L; Barrios A; Barreiro P; Blanco F; García-Benayas T; González-Lahoz J HIV Clin Trials; 2002; 3(3):186-94. PubMed ID: 12032877 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China]. Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383 [TBL] [Abstract][Full Text] [Related]
15. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial. Barrios A; Negredo E; Domingo P; Estrada V; Labarga P; Asensi V; Morales D; Santos J; Clotet B; Soriano V; Antivir Ther; 2005; 10(7):825-32. PubMed ID: 16312178 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Negredo E; Moltó J; Muñoz-Moreno JA; Pedrol E; Ribera E; Viciana P; Galindos MJ; Miralles C; Burger D; Rodriguez Fumaz C; Puig J; Gel S; Rodríguez E; Videla S; Ruiz L; Clotet B Antivir Ther; 2004 Jun; 9(3):335-42. PubMed ID: 15259896 [TBL] [Abstract][Full Text] [Related]
17. Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients. Skowron G; Kuritzkes DR; Thompson MA; Squires KE; Goodwin SD; Dusak BA; Tolson JM; Stevens M; Yuen GJ; Rooney JF; J Infect Dis; 2002 Oct; 186(7):1028-33. PubMed ID: 12232846 [TBL] [Abstract][Full Text] [Related]